
The expanded approval adds a self-administered autoinjector option and new label language tying LDL-C lowering to reduced cardiovascular risk.

The expanded approval adds a self-administered autoinjector option and new label language tying LDL-C lowering to reduced cardiovascular risk.

The year 2026 has brought a stark paradox to American pharmacy practice, and it’s affecting the most sought-after prescription drugs on the market.

The approval gives pharmacists a new, nonegg-based seasonal influenza option for adults 50 and older ahead of the 2026-2027 flu season.

Oveporexton, an oral orexin receptor 2 agonist, is the first medicine to restore orexin signaling rather than manage symptoms of the rare sleep disorder.

This medication is the first FDA-approved OTC innovation in the cold and flu category in 14 years.

The rapid-acting insulin aspart biosimilar adds a third interchangeable option to NovoLog, with implications for pharmacy dispensing and counseling.

Viatris' new transdermal patch adds a low-dose estrogen option to the contraceptive landscape.

The opioid-free product pairs acetaminophen with naproxen in a single dose, giving pharmacists a new counseling point for patients.

The approval is backed by pivotal phase 3 trials and carries boxed warnings for suicidal ideation in pediatric patients and abuse potential.

In the first of a 2-day hearing on peptide therapy access, the FDA votes in favor of approving 4 of the products discussed, with the potential for more on Friday.

Lipfendra (enlicitide) showed placebo-adjusted low-density lipoprotein cholesterol reductions of more than 50% in 2 phase 3 trials.

Subcutaneous lecanemab-irmb can now be self-administered or given by a caregiver from the first dose, eliminating the requirement for an initial in-clinic intravenous infusion.

Atacicept-vymj is the first medication for immunoglobulin A nephropathy that targets both B cell activating factor and a proliferation-inducing ligand inhibitors.

FDA staff review recommends against adding 7 peptides to the 503A bulk list, citing gaps in characterization, effectiveness, and safety data.

The approval extends risankizumab to children 6 years and older and introduces a new weight-based 55 mg prefilled syringe.

This approval provides pharmacists with an option for patients whose levels remain refractory to lifestyle and standard medication.

The first generic rifapentine expands affordable treatment for active and latent tuberculosis.

This episode highlights the FDA’s announcement regarding GLP-1 supply stabilization and critical compliance strategies for 503A pharmacies.

FDA advisors back Moderna’s mRNA flu shot for older adults, hinting at a potential egg-free option for 2026–2027.

The pneumococcal vaccine is approved for protection against 21 serotypes in adults over 18 and children between 2 and 17 at high risk of disease.

FDA clears first generic Xofluza tablet, bringing affordable single-dose flu treatment and prevention.

GSK and Spero Therapeutics’ newly approved carbapenem could be a standard of care in adults with complicated urinary tract infections who prefer oral administration.

A study examining naloxone sales found that retail OTC sales have been surprisingly limited despite improvements in access.

This decision marks a milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells.

FDA clears first OTC CGM for children 2 years and older, expanding tracking beyond prescriptions for pediatric populations.

Lebrikizumab enables 8‑week maintenance dosing for severe eczema, reducing injections to 6 yearly while maintaining strong skin‑clearance results.

Reports state that everyone from “shadowy online vendors” to physicians and nurses is illegally promoting the drug before it receives proper FDA approval.

The decision represents the first new sunscreen ingredient permitted in the United States since the late 1990s.

Pharmacists help women choose safer hormone replacement therapy or nonhormonal relief options.

The approval arrives prior to the Prescription Drug User Fee Act action date of June 16, 2026.